Faricimab不同剂量方案对比雷珠单抗治疗新生血管性年龄相关性黄斑变性的安全性与疗效:AVENUE 2期随机临床试验
AVENUE是一项在美国58个中心开展的36周、多剂量方案、阳性对照、双盲2期随机研究,纳入263例未接受过抗VEGF治疗的新生血管性AMD患者。比较faricimab不同剂量方案与雷珠单抗0.5mg每4周在36周时BCVA变化,结果显示faricimab未达到优于雷珠单抗的主要终点,但视觉和解剖学获益支持开展3期试验,且未发现新的安全性信号。
要点
- Faricimab总体视觉和解剖学获益与雷珠单抗相当,支持进一步3期试验。
- Faricimab未显示新的或非预期安全性信号。
核心结论
- AVENUE研究未达到faricimab在36周BCVA上优于雷珠单抗的主要终点。
- Faricimab虽不优于每月雷珠单抗,但视觉和解剖学获益支持开展3期试验作为每月抗VEGF治疗的潜在替代方案。
- Faricimab未显示新的或非预期安全性信号。
研究设计与样本
- AVENUE为36周、多剂量方案、阳性对照、双盲2期随机临床研究,在美国58个中心开展。
- 纳入未接受过抗VEGF治疗、继发于nAMD的脉络膜新生血管患者,BCVA ETDRS字母评分73(Snellen等效20/40)至24(Snellen等效20/320)。
- 共263例参与者纳入分析(172例[65.4%]女性;258例[98.1%]白人;平均[SD]年龄78.3[8.7]岁)。
- 患者按3:2:2:2:3随机分配至A组(雷珠单抗0.5mg每4周,n=68)、B组(faricimab 1.5mg每4周,n=47)、C组(faricimab 6.0mg每4周,n=42)、D组(faricimab 6.0mg每4周至第12周后改为6.0mg每8周,n=47)、E组(雷珠单抗0.5mg每4周至第8周后改为faricimab 6.0mg每4周,n=69)。
临床怎么用
- Faricimab在36周时未显示优于每月雷珠单抗的BCVA获益,尚不支持将其作为优于现有方案的常规选择。
- Faricimab总体视觉和解剖学获益与雷珠单抗相当且安全性可接受,可作为每月抗VEGF治疗的潜在替代方案进一步研究。
局限性
- 为2期研究,样本量263例,随访36周,结果需3期试验验证。
- 研究人群以白人(98.1%)和女性(65.4%)为主,外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Faricimab, the first bispecific antibody designed for intraocular use, simultaneously and independently binds and neutralizes angiopoietin 2 (Ang-2) and vascular endothelial growth factor A (VEGF-A). OBJECTIVE: To assess the efficacy and safety of different doses and regimens of faricimab vs ranibizumab in patients with neovascular age-related macular degeneration (nAMD). DESIGN, SETTING, AND PARTICIPANTS: AVENUE was a 36-week, multiple-dose-regimen, active comparator-controlled, double-masked, phase 2 randomized clinical study performed at 58 sites in the United States. Eligible participants were anti-VEGF treatment naive with choroidal neovascularization secondary to nAMD and best-corrected visual acuity (BCVA) Early Treatment Diabetic Retinopathy Study (ETDRS) letter score of 73 (Snellen equivalent, 20/40) to 24 (Snellen equivalent, 20/320). Data were collected from August 11, 2015, to January 12, 2017, with the final patient visit completed September 26, 2017. Data were analyzed from August 11, 2015, to October 4, 2019. INTERVENTIONS: Patients were randomized 3:2:2:2:3 to receive ranibizumab, 0.5 mg every 4 weeks (arm A [n = 68]); faricimab, 1.5 mg every 4 weeks (arm B [n = 47]); faricimab, 6.0 mg every 4 weeks (arm C [n = 42]); faricimab, 6.0 mg every 4 weeks until week 12, then faricimab, 6.0 mg every 8 weeks (arm D [n = 47]); and ranibizumab, 0.5 mg every 4 weeks until week 8, then faricimab, 6.0 mg every 4 weeks (arm E [n = 69]). MAIN OUTCOMES AND MEASURES: Mean change in BCVA from baseline to week 36, proportion of participants gaining at least 15 letters, BCVA of 20/40 or better or 20/200 or worse, and ocular coherence tomographic outcomes in anti-VEGF treatment-naive participants (arms A, B, C, D) and from weeks 12 to 36 in those with incomplete response (participants in arms A and E with week 12 BCVA ETDRS letter score of ≤68 [Snellen equivalent, 20/50 or worse]). RESULTS: A total of 263 participants were included in the analysis (172 [65.4%] female; 258 [98.1%] white; mean [SD] age, 78.3 [8.7] years). At week 36, adjusted mean change in BCVA vs ranibizumab was 1.6 (80% CI, -1.6 to 4.7) letters for arm B (P = .52), -1.6 (80% CI, -4.9 to 1.7) letters for arm C (P = .53), and -1.5 (80% CI, -4.6 to 1.6) letters for arm D (P = .53). For arm E, adjusted mean change from week 12 was -1.7 (80% CI, -3.8 to 0.4) letters (P = .30). CONCLUSIONS AND RELEVANCE: AVENUE did not meet its primary end point of superiority of faricimab over ranibizumab in BCVA at week 36. Although not superior to monthly ranibizumab as given in this trial, overall visual and anatomical gains noted with faricimab support pursuing phase 3 trials for a potential alternative to monthly anti-VEGF therapy. Faricimab showed no new or unexpected safety signals. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02484690.
引用
- Sahni J, Dugel PU, Patel SS, et al. Safety and Efficacy of Different Doses and Regimens of Faricimab vs Ranibizumab in Neovascular Age-Related Macular Degeneration: The AVENUE Phase 2 Randomized Clinical Trial. JAMA Ophthalmol. 2020. PMID: 32729888. doi:10.1001/jamaophthalmol.2020.2685
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。